Pacira reported $0.7 in EPS Earnings Per Share for its fiscal quarter ending in September of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2026 0.70 0.76 0.70 Nov/09
FY2026Q2 Jun/2026 0.73 0.65 0.74 Aug/04
FY2026Q1 Mar/2026 0.60 0.73 0.62 Apr/30
FY2025Q4 Dec/2025 0.91 0.91 Feb/26
FY2025Q3 Sep/2025 0.70 0.66 0.79 Nov/06




Eps Change Date
Astellas Pharma JPY 55.69 23.46 Sep/2026
Bristol-Myers Squibb USD 1.35 0.69 Sep/2026
Cara Therapeutics USD -0.72 0.14 Mar/2026
Coherus Biosciences USD -0.43 0.06 Dec/2025
Heron Therapeutics USD -0.02 0.02 Dec/2025
Ironwood Pharmaceuticals USD 0.31 0.07 Jun/2026
J&J USD 2.7 0.2 Sep/2026
Ligand Pharmaceuticals USD 2.67 0.3 Sep/2026
Nektar Therapeutics USD -1.78 0.43 Mar/2026
Novo Nordisk DKK 4.74 6.17 Jun/2026
Omeros USD -1.12 0.37 Jun/2024
Pacira USD 0.7 0.03 Sep/2026
Perrigo USD 0.6 0.1 Sep/2026
Pfizer USD 0.87 0.1 Sep/2026
Supernus Pharmaceuticals USD 0.35 1.36 Sep/2026
Teva Pharmaceutical Industries USD 0.79 0.73 Sep/2026
Xeris Pharmaceuticals USD -0.18 0.19 Jun/2026
Zoetis USD 1.75 0.12 Sep/2026